Russia approves Sputnik V Covid-19 vaccination with flu shot

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

The Health Ministry of Russia has reportedly granted approval for administering Covid-19 vaccine Sputnik V and flu shots simultaneously, making changes to the instruction for the vaccine use.

Studies have demonstrated that the joint administration of both vaccines has not reduced their effectiveness.

Russian news agency TASS quoted Health Ministry as saying in a statement: “The combination of Sputnik V with the influenza vaccine has been studied in preclinical trials, showing no decrease in immunogenicity of both vaccines when they are administered simultaneously.

“When Covid-19 and flu vaccines are administered simultaneously, the shots are injected to different parts of the body, for example, the left and right shoulders.”

The Gamaleya National Research Institute of Epidemiology and Microbiology has developed the Sputnik V vaccine based on a human adenovirus vector platform.

The vaccine uses two different human adenoviral vectors to enhance the immune response and provide immunity that lasts long. It secured approval for use in 70 countries globally.

Recently, the World Health Organization (WHO) has kept Sputnik V’s Emergency Use Listing (EUL) process, on hold due to pending legal procedures and missing data.

WHO assistant director-general for access to medicines and health products Mariangela Simao stated that the vaccine’s case will be reopened and the submitted data will be evaluated even though it is not complete, only after reaching an agreement.

Simao further added that inspections of manufacturing sites in Russia will resume.

The Russian Direct Investment Fund and Gamaleya have also announced that the one-shot Sputnik Light vaccine demonstrated an effectiveness of 70% against the Delta variant of the virus following three months of vaccination.

Latest stories

Related stories

API China, PHARMCHINA & NHNE 2025 Conclude with Global Win

API China, PHARMCHINA & NHNE 2025 Close in Guangzhou...

Under-Eye Wrinkle Treatment: How to Reduce Puffiness and Fine Lines

As we age, the skin around our eyes begins...

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back